Bensink, Mark <br/><br/>
Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083-93.  [electronic resource] 

 -  Journal of medical economics  06 2018 
 - 603-605 p.  digital 
<br/><br/> Publication Type: Journal Article; Comment 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.1080/13696998.2018.1452747  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents<br/>Biosimilar Pharmaceuticals<br/>Filgrastim<br/>Humans<br/>Polyethylene Glycols